Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imaging-guided photothermal therapy
Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imaging-guided photothermal therapy
复制标题
近红外染料结合白蛋白具有独立的成像和治疗波长通道，用于成像引导光热治疗
DOI：
10.1016/j.biomaterials.2014.06.013
复制
发表时间：
2014-09-01
期刊：
影响因子：
14
通讯作者：
Liu, Zhuang
中科院分区：
文献类型：
--
作者：
Chen, Qian;Wang, Chao;Liu, Zhuang
用于成像引导光热治疗的治疗诊断剂的开发引起了 napomedicine 领域的极大兴趣。然而，如果使用相同波长的光进行荧光成像和光热消融，则成像和治疗对药剂的量子产率（QY）的要求存在争议。在这项工作中，我们合成的近红外染料IR825与人血清白蛋白（HSA）结合，形成HSA-IR825复合物，其在600 nm激发下的荧光大大增强，与游离IR825相比增强了100倍，并且在808 nm处具有相当高的吸光度但荧光QY较低。由于荧光成像所需的高 QY 会导致光热转换效率降低，因此 HSA-IR825 独特的光学行为能够在不同波长下实现成像和光热治疗，并具有优化的性能。因此，我们使用 HSA-IR825 在动物肿瘤模型中进行成像引导光热治疗。体内荧光成像显示，HSA-IR825 静脉注射后显示出高肿瘤摄取，这可能是由于增强的渗透性和保留效应，以及在其他器官中的低水平保留。虽然 HSA 是人血清中丰富的蛋白质，但高效液相色谱 (HPLC) 证明，IR825 能够通过肾脏排泄。最终用HSA-IR825进行了体内肿瘤治疗实验，用较低剂量的IR825实现了小鼠100%的肿瘤消融。我们的工作提出了一种安全、简单且可成像的光热纳米探针，有望用于未来癌症治疗的临床转化。 (C) 2014 Elsevier Ltd. 保留所有权利。
Development of theranostic agent for imaging-guided photothermal therapy has been of great interest in the field of napomedicine. However, if fluorescent imaging and photothermal ablation are conducted with the same wavelength of light, the requirements of the agent's quantum yield (QY) for imaging and therapy are controversial. In this work, our synthesized near-infrared dye, IR825, is bound with human serum albumin (HSA), forming a HSA-IR825 complex with greatly enhanced fluorescence under 600 nm excitation by as much as 100 folds compared to that of free IR825, together with a rather high absorbance but low fluorescence QY at 808 nm. Since high QY that is required for fluorescence imaging would result in reduced photothermal conversion efficiency, the unique optical behavior of HSA-IR825 enables imaging and photothermal therapy at separated wavelengths both with optimized performances. We thus use HSA-IR825 for imaging-guided photothermal therapy in an animal tumor model. As revealed by in vivo fluorescence imaging, HSA-IR825 upon intravenous injection shows high tumor uptake likely owing to the enhanced permeability and retention effect, together with low levels of retentions in other organs. While HSA is an abundant protein in human serum, IR825 is able to be excreted by renal excretion as evidenced by high-performance liquid chromatography (HPLC). In vivo tumor treatment experiment is finally carried out with HSA-IR825, achieving 100% of tumor ablation in mice using a rather low dose of IR825. Our work presents a safe, simple, yet imageable photothermal nanoprobe, promising for future clinical translation in cancer treatment. (C) 2014 Elsevier Ltd. All rights reserved.